Intraocular inflammation with intravitreal bevacizumab (Avastin)

Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents, 2 3 as ranibizumab (Lucentis) is now the standard of care for neovascular age-related macular degeneration according to NICE UK recommendations. 4 5 However, the spectrum of off-label therapeutic indica...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of ophthalmology 2010-04, Vol.94 (4), p.525-525
Hauptverfasser:	Raja, Muhammad S, Goldsmith, Craig, Burton, Benjamin J L
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Female Humans Inflammation Intravitreal Injections Macular degeneration Neovascularisation Ranibizumab Uveitis - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!